(ANVS) Annovis Bio - Ratings and Ratios

Annovis Bio, Inc. (NYSE:ANVS) is a clinical-stage biotechnology company focused on developing innovative therapies for neurodegenerative diseases. The companys lead candidate, Buntanetap, has completed Phase 1/2 clinical trials for Alzheimers disease (AD), Parkinsons disease, and other chronic neurodegenerative conditions. Buntanetap targets pathways associated with neurotoxicity and inflammation, aiming to slow or halt disease progression. Annovis is also advancing ANVS405, an intravenous drug in Phase 2 and Phase 3 efficacy studies for traumatic brain injury (TBI) and stroke, designed to protect brain cells from further damage. Additionally, ANVS301, an orally administered drug, is in Phase 1 clinical trials to enhance cognitive function in later-stage AD and dementia patients. Founded in 2008, Annovis Bio operates from its headquarters in Malvern, Pennsylvania, and is committed to addressing unmet needs in neurodegenerative medicine.

Web URL: https://www.annovisbio.com

3-Month Forecast: Based on and , ANVS is expected to face continued volatility. The stock is currently trading below its 20-day, 50-day, and 200-day moving averages ($2.21, $3.76, $7.03 respectively), indicating bearish momentum. Average volume of 559,965 shares suggests moderate liquidity, while the ATR of 0.31 signals moderate price movement expectations. Fundamentally, the companys market cap of $35.66M and P/B ratio of 5.05 reflect its speculative nature and high-risk profile. With no P/E or P/S ratios due to lack of earnings, investors should focus on clinical trial progress and broader market sentiment for near-term direction.